Why ASX retail investors are watching Energy Resources of Australia (ASX: ERA) collapse to the Rio Tinto buyout floor
Read More Pharma Industry News GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more. byVenkateshMarch 9, 2026